Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Needham has maintained its Buy rating for Blueprint Medicines (NASDAQ:BPMC) and increased its price target from $66.00 to $74.00. Blueprint Medicines shares are currently trading up 4.09% at $57.48 per share. A move to $74.00 would represent a 28.74% increase from the current share price.
October 27, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham's maintained Buy rating and increased price target for Blueprint Medicines could potentially drive the stock price up in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and trading behavior. Needham's decision to maintain a Buy rating and raise the price target for BPMC suggests a positive outlook for the stock, which could potentially drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100